

**NOTE: As provided in LFC policy, this report is intended for use by the standing finance committees of the legislature. The Legislative Finance Committee does not assume responsibility for the accuracy of the information in this report when used in any other situation.**

**Only the most recent FIR version, excluding attachments, is available on the Intranet. Previously issued FIRs and attachments may be obtained from the LFC office in Suite 101 of the State Capitol Building North.**

## FISCAL IMPACT REPORT

SPONSOR:	Jennings	DATE TYPED:	02/07/00	HB	
SHORT TITLE:	Amend Patient Protection Act			SB	430
				ANALYST:	Valenzuela

### APPROPRIATION

Appropriation Contained		Estimated Additional Impact		Recurring or Non-Rec	Fund Affected
FY00	FY01	FY00	FY01		
	NFI		NFI		

(Parenthesis ( ) Indicate Expenditure Decreases)

Duplicates/Conflicts with/Companion to/Relates to

### SOURCES OF INFORMATION

LFC Files

Public Regulation Commission (PRC)

### SUMMARY

### Synopsis of Bill

Senate Bill 430 amends Section 4 of the Patient Protection Act by requiring managed health care plans to provide coverage for FDA-approved experimental or investigational procedures if a physician recommends them as medically necessary to preserve the life of the patient.

### Significant Issues

Managed health care plans would likely increase its premiums to implement this program, if it does not already provide the coverage.

### **FISCAL IMPLICATIONS**

Enactment of Senate Bill 430 would have only a minimal fiscal impact, in terms of enacting rules to implement this legislative change. The agency would be able to absorb the impact with its existing resources.

### **ADMINISTRATIVE IMPLICATIONS**

See above statement.

MFV/njw